Biodexa Pharmaceuticals Appoints Fiona Sharp as New CFO and Director
BDRX is trading near its 52-week low of $2.22 (8.1% above the low).
Summary
Biodexa Pharmaceuticals Plc appointed Fiona Sharp, its former Group Financial Controller, as Chief Financial Officer and a Director, allowing CEO Stephen Stamp to focus on his primary role.
Key Events · Executive and Board Changes · BDRX
-
New Chief Financial Officer Appointed
Fiona Sharp, previously the Group Financial Controller, has been appointed as Chief Financial Officer and Corporate Secretary, effective January 5, 2026.
-
Board Appointment
Ms. Sharp will also join the Board of Directors, serving until the Company's annual general meeting in 2026.
-
CEO Focuses on Core Role
Stephen Stamp has relinquished his CFO and Corporate Secretary positions to focus exclusively on his role as Chief Executive Officer.
Analysis · BDRX · Life Sciences
Biodexa Pharmaceuticals Plc has strengthened its executive leadership by appointing Fiona Sharp, previously the Group Financial Controller, as Chief Financial Officer and a member of the Board of Directors. This move allows Stephen Stamp to focus solely on his role as Chief Executive Officer, enhancing management specialization. Ms. Sharp's internal experience and background as a Chartered Certified Accountant are crucial for financial oversight and strategic planning, particularly for a company of Biodexa's size.
At the time of this filing, BDRX was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $2.22 to $92.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.